Patient | Stage | Treatment | MALT Response After 12 Weeks | Progression/Time to Lymphoma | Progression, mo SS | Retreatment | Response | Survival/mo |
---|---|---|---|---|---|---|---|---|
1* | L | Watchful waiting | SD | Yes/81 | No | Surgery | CR | Alive/153 |
2 | L | Watchful waiting | SD | No | No | Deceased/109† | ||
3 | DD | Surgery | SD | No | No | Alive/141 | ||
4 | L | Surgery | CR | Yes/85 | No | R-CP | CR | Alive/124 |
5 | L | Watchful waiting | SD | No | No | Alive/128 | ||
6 | L | Surgery & radiotherapy | CR | No | No | Alive/102 | ||
7 | L | Watchful waiting | SD | No | No | Alive/108 | ||
8* | LD | Rituximab | CR | No | Yes/27 | CYC | Stable | Alive/91 |
9 | L | Rituximab | SD | No | No | Alive/78 | ||
10* | LD | Radiotherapy | SD | Yes/98 | Yes/98 | CYC | Stable | Alive/153 |
11 | L | Rituximab | CR | No | No | Alive/141 | ||
12 | L | Rituximab | CR | No | No | Alive/75 | ||
13* | L | Rituximab | SD | Yes/4 | Yes/4 | Rituximab | Stable | Alive/66 |
14* | LD | Rituximab | CR | Yes/52 | No | Rituximab | Stable | Alive/70 |
15 | LD | Surgery | SD | Yes/73 | No | Radiotherapy | CR | Alive/100 |
16 | L | Rituximab | CR | No | No | Alive/94 | ||
17 | L | Rituximab | SD | No | No | Alive/83 | ||
18 | L | Rituximab | SD | No | No | Alive/64 | ||
19 | L | Rituximab | SD | No | No | Alive/67 | ||
20 | L | Watchful waiting | SD | No | No | Alive/64 | ||
21 | L | Rituximab | PR | Yes/9 | No | Rituximab | Stable | Alive/57 |
22 | L | Rituximab | SD | No | No | Alive/58 | ||
23 | DD | Surgery & radiotherapy | CR | Yes/39 | No | R-CP | Stable | Alive/85 |
24 | L | Watchful waiting | SD | No | No | Alive/75 | ||
25 | LD | Watchful waiting | SD | No | No | Alive/53 | ||
26 | L | R-CP | CR | No | No | Alive/49 | ||
27 | L | Watchful waiting | SD | No | No | Alive/46 | ||
28* | DD | R-CP | CR | No | No | Alive/50 | ||
29* | DD | R-CP | CR | Yes/15 | No | Radiotherapy | CR | Alive/47 |
30 | L | Watchful waiting | SD | Yes/34 | No | Radiotherapy | CR | Alive/50 |
31 | L | R-CP | CR | No | No | Alive/36 | ||
32 | L | R-CP | CR | No | No | Alive/28 | ||
33 | L | Watchful waiting | SD | No | No | Alive/28 | ||
34 | L | R-CP | CR | No | No | Alive/26 | ||
35 | L | Rituximab | SD | No | No | Alive/16 |
↵* High SS disease activity.
↵† Patient died of pneumonia unrelated to MALT lymphoma. L: localized disease; LD: locally disseminated; DD: disseminated disease; CR: complete response; SD: stable disease; PR: partial response; R-CP: rituximab with cyclophosphamide and prednisone; CYC: cyclophosphamide.